Xeris Biopharma Holdings, Inc. XERS
Xeris Biopharma Holdings, Inc. along with its subsidiaries, is referenced herein as the "Company", "Xeris", "Xeris Biopharma", "we" or "our". Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M | $20.2M | — |
| R&D | $31.2M | $25.6M | $22.3M | $21.0M | $25.2M | $20.9M | — |
| SG&A | $182.4M | $163.5M | $146.1M | $137.7M | $125.7M | $73.7M | — |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | -$115.2M | -$83.5M | — |
| Interest expense | $29.1M | $30.5M | $26.6M | $14.1M | $7.2M | $10.7M | — |
| Pre-tax income | $554.0K | -$57.1M | -$63.5M | -$96.1M | -$122.7M | -$91.0M | — |
| Income tax | $0 | $2.3M | $1.2M | $1.4M | $0 | $110.0K | — |
| Net income | $554.0K | -$54.8M | -$62.3M | -$94.7M | -$122.7M | -$91.1M | — |
| EPS, basic | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | — | — |
| EPS, diluted | 0.00 | -0.37 | -0.45 | -0.70 | -1.55 | -2.14 | — |
| Shares, diluted (wtd. avg.) | $172.7M | $146.8M | $137.7M | $135.6M | $79.0M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $111.0M | $71.6M | $67.4M | $126.3M | $67.3M | $37.6M | $19.5M |
| Short-term investments | — | $0 | $5.0M | $0 | $35.2M | $96.2M | — |
| Receivables | $51.0M | $40.4M | $39.2M | $30.8M | $17.5M | $6.9M | — |
| Inventory | $68.7M | $48.2M | $38.8M | $24.7M | $18.1M | $8.4M | — |
| Total current assets | $240.3M | $167.7M | $156.3M | $186.8M | $142.6M | $152.2M | — |
| Property, plant and equipment | $4.9M | $5.6M | $6.0M | $5.5M | $6.6M | $6.7M | — |
| Goodwill | $22.9M | $22.9M | $22.9M | $22.9M | $22.9M | $0 | — |
| Other intangibles | $88.1M | $98.9M | $109.8M | $120.6M | $131.4M | $0 | — |
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M | $159.2M | — |
| Accounts payable | $3.1M | $2.3M | $11.6M | $4.6M | $8.9M | $3.1M | — |
| Short-term debt | $0 | $15.1M | $0 | — | — | — | — |
| Total current liabilities | $109.6M | $100.4M | $95.2M | $73.6M | $79.0M | $28.2M | — |
| Long-term debt | $220.3M | $217.0M | $190.9M | $187.1M | $88.1M | $87.0M | — |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M | $125.4M | — |
| Retained earnings | -$671.3M | -$671.9M | -$617.0M | -$554.8M | -$460.1M | -$337.4M | — |
| Total equity | $13.7M | -$29.6M | -$6.8M | $45.2M | $95.2M | $33.8M | $14.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M | -$80.6M | — |
| Depreciation and amortisation | $1.3M | $1.2M | $1.5M | $1.4M | $1.3M | $1.5M | — |
| Stock-based compensation | $22.4M | $18.4M | $10.7M | $12.2M | $11.4M | $8.3M | — |
| Capital expenditure | — | — | — | — | $1.1M | $377.0K | — |
| Investing cash flow | -$696.0K | $4.9M | -$6.0M | $34.5M | $98.0M | -$27.4M | — |
| Financing cash flow | $11.4M | $36.2M | -$1.6M | $127.5M | $27.2M | $126.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001867096-26-000021.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |